Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
MOTS-c (40 mg Vial) Metabolic regulator enhancing insulin sensitivity and fat oxidation.
The freeze-dried format helps maintain research material integrity during storage and transport in qualified laboratory settings
Week 4-8: Progressive improvement for responders
Seniors using our geriatric medical services sometimes find that injections help maintain healthy levels when a deficiency is confirmed
US$ 21.03
US$ 29.26
US$ 25.66
US$ 26.63
US$ 23.21
